Different types of dyslipidemia in type 2 diabetes and the associated factors
Öz
Aim: Diabetes and dyslipidemia are common diseases that can be seen together. In this study, we aimed to investigate factors affecting the type of dyslipidemia in diabetic patients.
Methods: The cross-sectional study included a total of 596 patients with type 2 diabetes who visited the outpatient diabetes clinic of the Istanbul Medeniyet University between January 2017 and December 2019. Patient laboratory, clinical, and sociodemographic data were retrieved from medical records.
Results: Of all patients, 52% were diagnosed with hypercholesterolemia (total cholesterol ≥200 mg/dL) and 56.4% had a history of hypertriglyceridemia. Four hundred and forty-four (74%) patients had abnormal low-density lipoprotein cholesterol (LDL-C) levels (≥100 mg/dL). Eighty percent of the female patients and 67.4% of the male patients had abnormal LDLC levels, and the difference between the two sexes was statistically significant (p<0.001). Triglyceride levels were higher in the patients with a hemoglobin A1c (HBA1c) level ≥7% (p<0.001). Smokers had significantly higher levels of LDL-C (p=0.03) and lower levels of high-density lipoprotein cholesterol (p=0.038) than non-smokers. The mean body mass index was higher for the group of non-smokers than for the smokers (p<0.001). The rates of hypertriglyceridemia and obesity were significantly higher in patients with hypertension than in those without (p=0.036 and p=0.013, respectively).
Conclusion: Dyslipidemia is common in diabetic patients, especially women. A complete examination of the patient should include the consideration of conditions associated with dyslipidemia.
Anahtar Kelimeler
diabetes, dyslipidemia, hypercholesterolemia, hypertriglyceridemia
Kaynakça
- The World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.
- Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–76.
- Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.
- O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case–control study. Lancet. 2016;388:761–75.
- Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120(3):8–12.
- Phillips GB. Sex hormones, risk factors and cardiovascular disease. Am J Med. 1978;65(1):7– 11.
- The American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(1):14–31.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
- UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20(11):1683–7.
- Abacı A, Kılıçkap M, Göksülük H, Karaaslan D, Barçın C, Kayıkçıoğlu M, et al. Türkiye’de metabolik sendrom sıklığı verileri: kardiyovasküler risk faktörlerine yönelik epidemiyolojik çalışmaların sistematik derleme, meta-analiz ve meta-regresyonu. Türk Kardiyoloji Derneği Arşivi. 2018;46(7):591–601.